Literature DB >> 25424910

The PPARα pathway in Vγ9Vδ2 T cell anergy.

Mary Poupot1, Frédéric Boissard, Delphine Betous, Laure Bardouillet, Séverine Fruchon, Fatima L'Faqihi-Olive, Frédéric Pont, Mourad Mekaouche, Sophie Ingoure, Hélène Sicard, Guy Dubreuilh, Jean-Jacques Fournié.   

Abstract

Phosphoantigens (PAgs) activate Vγ9Vδ2 T lymphocytes, inducing their potent and rapid response in vitro and in vivo. However, humans and nonhuman primates that receive repeated injections of PAgs progressively lose their Vγ9Vδ2 T cell response to them. To elucidate the molecular mechanisms of this in vivo desensitization, we analyzed the transcriptome of circulating Vγ9Vδ2 T cells from macaques injected with PAg. We showed that three PAg injections induced the activation of the PPARα pathway in Vγ9Vδ2 T cells. Thus, we analyzed the in vitro response of Vγ9Vδ2 T cells stimulated with a PPARα agonist. We demonstrated that in vitro PPARα pathway activation led to the inhibition of the BrHPP-induced activation and proliferation of human Vγ9Vδ2 T cells. Since the PPARα pathway is involved in the antigen-selective desensitization of human Vγ9Vδ2 T cells, the use of PPARα inhibitors could enhance cancer immunotherapy based on Vγ9Vδ2 T cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25424910      PMCID: PMC6275808          DOI: 10.2478/s11658-014-0218-0

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  2 in total

1.  Synergistic effect of IL-12 and IL-18 induces TIM3 regulation of γδ T cell function and decreases the risk of clinical malaria in children living in Papua New Guinea.

Authors:  Louis Schofield; Lisa J Ioannidis; Stephan Karl; Leanne J Robinson; Qiao Y Tan; Daniel P Poole; Inoni Betuela; Danika L Hill; Peter M Siba; Diana S Hansen; Ivo Mueller; Emily M Eriksson
Journal:  BMC Med       Date:  2017-06-15       Impact factor: 8.775

2.  Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma.

Authors:  Xiaoguang Qi; Chunyan Qi; Xindan Kang; Yi Hu; Weidong Han
Journal:  PeerJ       Date:  2020-06-17       Impact factor: 2.984

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.